Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Ligand Pharmaceuticals Inc

+ Add to Watchlist

LGND:US

56.9200 USD 0.1100 0.19%

As of 20:10:00 ET on 01/30/2015.

Snapshot for Ligand Pharmaceuticals Inc (LGND)

Open: 56.9300 Day's Range: 55.3300 - 58.6600 Volume: 318,111
Previous Close: 57.0300 52wk Range: 41.9900 - 80.4200 1-Yr Rtn: -8.10%

Stock Chart for LGND

No chart data available.
  • LGND:US 56.9200
  • 1D
  • 1M
  • 1Y
57.0300
Interactive LGND Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for LGND

Current P/E Ratio (ttm) 166.2820
Estimated P/E(12/2014) 50.2383
Relative P/E vs. SPX 9.4653
Earnings Per Share (USD) (ttm) 0.3423
Est. EPS (USD) (12/2014) 1.1330
Est. PEG Ratio 1.6746
Market Cap (M USD) 1,139.72
Shares Outstanding (M) 20.02
30 Day Average Volume 250,951
Price/Book (mrq) 25.8060
Price/Sale (ttm) 20.7707
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 15.0000
Dividend Ex-Date 04/03/2007
5 Year Dividend Growth -
Next Earnings Announcement 02/09/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for LGND

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for LGND

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.

John L HigginsPresident/CEOMatthew W Foehr "Matt"Exec VP/COO
Nishan De SilvaVP:Finance & Strategy/CFOCharles S BerkmanVP/Secretary/General Counsel
More Company Profile & Key Executives for LGND

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil